Kay Olmstead
Direktor/Vorstandsmitglied bei BENO TNR, INC.
Profil
Kay Olmstead is the founder and current CEO & Director of Nano PharmaSolutions, Inc., a company founded in 2019.
She is also currently a Director at BENO TNR, Inc.
Aktive Positionen von Kay Olmstead
| Unternehmen | Position | Beginn |
|---|---|---|
| BENO TNR, INC. | Direktor/Vorstandsmitglied | - |
Nano Pharmasolutions, Inc.
 Nano Pharmasolutions, Inc. Pharmaceuticals: MajorHealth Technology Nano Pharmasolutions, Inc. is a pharmaceutical company based in an undisclosed location. Nano Pharmasolutions is developing a dry powder for inhalation (DPI) formulation of remedesivir to fight COVID-19. The American company's platform is based on physical vapor deposition (PVD) technology, which allows them to make drug nanoparticles with no excipients or solvents. These nanodrug particles can be used in various forms such as pills, nasal sprays, creams/salves, inhalers, and eye drops. The private company's nanotransformer™ technology can create an e-8 torr vacuum, and it uses carrier solids selected from hydrophilic pharmaceutical excipients to deposit vapor phase drugs as nanoparticles on fast-moving carriers. The company was founded by Kay Olmstead, Saeyeon Lee, Seok-Keun Koh, and Kay Olmstead has been the CEO since incorporation. | Gründer | 01.06.2019 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BENO TNR, INC. | Technology Services |
| Private Unternehmen | 1 |
|---|---|
Nano Pharmasolutions, Inc.
Nano Pharmasolutions, Inc. Pharmaceuticals: MajorHealth Technology Nano Pharmasolutions, Inc. is a pharmaceutical company based in an undisclosed location. Nano Pharmasolutions is developing a dry powder for inhalation (DPI) formulation of remedesivir to fight COVID-19. The American company's platform is based on physical vapor deposition (PVD) technology, which allows them to make drug nanoparticles with no excipients or solvents. These nanodrug particles can be used in various forms such as pills, nasal sprays, creams/salves, inhalers, and eye drops. The private company's nanotransformer™ technology can create an e-8 torr vacuum, and it uses carrier solids selected from hydrophilic pharmaceutical excipients to deposit vapor phase drugs as nanoparticles on fast-moving carriers. The company was founded by Kay Olmstead, Saeyeon Lee, Seok-Keun Koh, and Kay Olmstead has been the CEO since incorporation. | Health Technology |
